Intercept Pharmaceuticals, Inc. News Releases http://ir.interceptpharma.com/ Intercept Pharmaceuticals, Inc. News Releases en Intercept to Present at Upcoming Investor Conferences in June http://ir.interceptpharma.com/news-releases/news-release-details/intercept-present-upcoming-investor-conferences-june NEW YORK , May 30, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that its management will be presenting at the Thu, 30 May 2019 07:00:00 -0400 Intercept Pharmaceuticals, Inc. News Releases 12696 Intercept to Present at Upcoming Investor Conferences in May http://ir.interceptpharma.com/news-releases/news-release-details/intercept-present-upcoming-investor-conferences-may NEW YORK , May 10, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be presenting at the Fri, 10 May 2019 16:05:00 -0400 Intercept Pharmaceuticals, Inc. News Releases 12616 Intercept Pharmaceuticals Announces Pricing of Offerings of Common Stock and Convertible Senior Notes due 2026 http://ir.interceptpharma.com/news-releases/news-release-details/intercept-pharmaceuticals-announces-pricing-offerings-common NEW YORK , May 10, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it has priced its underwritten public Fri, 10 May 2019 08:30:00 -0400 Intercept Pharmaceuticals, Inc. News Releases 12606 Intercept Pharmaceuticals Announces Proposed Offerings of $200 Million of Common Stock and $200 Million of Convertible Senior Notes due 2026 http://ir.interceptpharma.com/news-releases/news-release-details/intercept-pharmaceuticals-announces-proposed-offerings-200 NEW YORK , May 08, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals , Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it is commencing an underwritten public Wed, 08 May 2019 16:05:00 -0400 Intercept Pharmaceuticals, Inc. News Releases 12586 Intercept Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update http://ir.interceptpharma.com/news-releases/news-release-details/intercept-pharmaceuticals-reports-first-quarter-2019-financial Positive results from pivotal Phase 3 REGENERATE study of OCA in patients with liver fibrosis due to NASH New Drug Application (NDA) filing in the U.S. for OCA in NASH projected in the third quarter of 2019   Worldwide Ocaliva net sales of $51.8 million in the first quarter of 2019 representing 47% Wed, 08 May 2019 07:00:00 -0400 Intercept Pharmaceuticals, Inc. News Releases 12576 Intercept to Announce First Quarter 2019 Financial Results on May 8, 2019 http://ir.interceptpharma.com/news-releases/news-release-details/intercept-announce-first-quarter-2019-financial-results-may-8 NEW YORK , May 01, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2019 financial results prior Wed, 01 May 2019 07:00:00 -0400 Intercept Pharmaceuticals, Inc. News Releases 12561 Intercept Reports Additional Positive Data from REGENERATE, the First Successful Phase 3 Study in NASH http://ir.interceptpharma.com/news-releases/news-release-details/intercept-reports-additional-positive-data-regenerate-first OCA significantly improved fibrosis in patients with liver fibrosis due to NASH and demonstrated consistent efficacy across multiple histologic and biochemical parameters REGENERATE data to be presented during the Opening Ceremony of EASL NEW YORK , April 11, 2019 (GLOBE NEWSWIRE) -- Intercept Thu, 11 Apr 2019 02:00:00 -0400 Intercept Pharmaceuticals, Inc. News Releases 12511 Intercept to Present Results from the First Successful Phase 3 Trial in Patients with Liver Fibrosis Due to NASH at the International Liver Congress™ 2019 http://ir.interceptpharma.com/news-releases/news-release-details/intercept-present-results-first-successful-phase-3-trial Multiple additional abstracts evaluating obeticholic acid (OCA) for the treatment of patients with progressive non-viral liver diseases to be presented at the meeting NEW YORK , April 04, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on Thu, 04 Apr 2019 07:00:00 -0400 Intercept Pharmaceuticals, Inc. News Releases 12501 Intercept to Present at Upcoming Investor Conferences http://ir.interceptpharma.com/news-releases/news-release-details/intercept-present-upcoming-investor-conferences-6 NEW YORK , March 05, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be presenting at the Tue, 05 Mar 2019 17:00:00 -0500 Intercept Pharmaceuticals, Inc. News Releases 12446 Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results, Issues 2019 Financial Guidance and Provides Business Update http://ir.interceptpharma.com/news-releases/news-release-details/intercept-pharmaceuticals-reports-fourth-quarter-and-full-year Positive topline results from pivotal Phase 3 REGENERATE study of obeticholic acid in patients with liver fibrosis due to NASH: the largest and first successful pivotal Phase 3 NASH study   Worldwide Ocaliva net sales of $52.9 million in the fourth quarter of 2018 and $177.8 million in the full Thu, 28 Feb 2019 07:15:00 -0500 Intercept Pharmaceuticals, Inc. News Releases 12411